SINCE 2014, SEN-JAM HAS BEEN ON A MISSION
TO REVOLUTIONIze INFLAMMATORY CARE
SINCE 2014, SEN-JAM HAS BEEN ON A MISSION
TO REVOLUTIONIze INFLAMMATORY CARE
Sen-Jam is Redefining Inflammatory Care for the Next Era of Medicine
We believe the future of healthcare starts upstream—by addressing inflammation at its root, not reacting to its consequences.
Since our founding in 2014, we’ve pursued one mission: to advance safe, effective solutions that help preserve health before disease takes hold. Our work targets a $10T global burden—where chronic inflammation drives the majority of modern illness, disability, and economic cost.
Our proprietary platform pairs proven molecules in novel ways to reshape inflammatory care—spanning applications from pain management to systemic inflammation, from consumer wellness to critical care. We focus relentlessly on non-opioid, non-suppressive therapeutics designed to work with the body’s natural systems—not against them.
Sen-Jam collaborates with visionary partners across science, distribution, and licensing. Together, we are building a future where healthcare moves upstream—preserving vitality, productivity, and quality of life at scale
Sen-Jam has been working hard building strategic partnerships, driving momentum and amassing 60+ both domestic and international patents and patents pending
2025
A Platform in Bloom
PAIR Technology, Patent Power & The Future of Anti-Inflammatories
In 2025, we began harvesting the fruits of a decade-long vision. Early results from our SJP-002C trial confirmed what we knew all along: treating inflammation at the source can transform outcomes for respiratory infections — and beyond. Meanwhile, SJP-001 evolved from a hangover prevention therapeutic into a powerful agent for metabolic recovery and balance. Now positioned to address the inflammatory impact of overindulgence in both food and alcohol, SJP-001 represents a new category of metabolic care — one rooted in resilience and restoration.
Our PAIR™ (Pleiotropic Anti-Inflammatory Regulators) technology is rapidly emerging as a clear differentiator in the anti-inflammatory space, backed by powerful new patents targeting metabolic disorders, obesity, and hospital setting immune resilience. Strategic investments from partners and a growing passionate community of retail investors helped fuel this next chapter. With a pipeline in full bloom, a platform ready to scale, and a public increasingly aligned with our mission, 2025 is becoming the year Sen-Jam steps confidently into its role as the next-gen leader in proactive, precision inflammation care.
Our Leadership Team
Masters of the science. Stewards of the mission. Innovating with the spirit of Good Karma Pharma.
We believe scientific excellence and commercial impact can—and must—coexist with integrity, empathy, and vision. That’s
the ethos driving everything we do.
Jacqueline Iversen, RPh, MS
Co-Founder, Chief Clinical Officer
Jackie has extensive knowledge and capabilities in a multitude of clinical settings. Her expertise involves providing clinical education across the healthcare continuum. In particular, upon completing a rigorous research fellowship in pharmacokinetics and pain at Memorial Sloan Kettering Cancer Center, Jackie saw new possibilities other colleagues and thought leaders missed. She is a passionate innovator and humanitarian with her eye always firmly on the ultimate impact to people in all places and stages of health and life.
Rute Fernandes
Executive Advisor
Rute is a globally experienced life sciences executive with a deep understanding of how innovation becomes impact. Her leadership spans more than 25 years across pharma, biotech, and tech, where she has guided organizations through commercialization, global launches, and large-scale transformation. Having held CEO, Board, and senior strategic roles at Novartis, Shire, and Takeda, Rute brings a rare blend of strategic clarity and operational excellence. She is a passionate advocate for accessible healthcare solutions and brings a human-centered approach to every challenge—always focused on creating meaningful value for patients, communities, and the future of global health.
Jim Iversen
Co-Founder/CEO
Jim is a Seasoned Executive and Charismatic Leader with a consistent track record of developing and executing business strategies that deliver rapid growth in sales, profits, market share, employee and customer satisfaction. He thrives in fast paced environments, producing results through remarkable resourcefulness and collaborations. A Strategic Powerhouse, Jim has a knack for seeing the big picture and stewarding multiple pathways to success. Client engagements range from start-ups to late stage, often resulting in an M&A transaction.
Thomas Dahl, PhD
Head of Product Development and Regulatory Affairs
Tom has held several senior management positions with companies ranging from start-ups to established global companies. He is an accomplished biotech/pharmaceutical executive with expertise in early stage ventures, including technical analysis of products and technologies, business strategy and operations, development program strategy, clinical trial design and interpretation, and interfacing with pharmaceutical partners.
Christine Leonard
Head of Strategic Communications
Christine is a highly respected and award-winning marcom strategist with passion for companies that aim to improve lives. She has led brand development, marketing execution, investor relations, consumer insight mining and communications excellence for world-class healthcare companies big and small. Christine has a unrelenting passion for collaborating with entrepreneurs who disrupt markets for massively good outcomes to humanity. She believes the world needs radically fresh solutions to age-old problems.
Neal Zahn
Head of Global Licensing
Wildly successful and seasoned executive in the manufacturing, operations and pharmaceutical industries, Neal is a powerhouse in global connection. With a strong bench of skills in the business development space, he has fine tuned his legendary resourcefulness in building long lasting, high impact strategic alliances. Neal is charming and unflappable, bringing optimism and pragmatism to the global stage.
"Arguably the world's most resourceful healthcare company.
Revolutionizing inflammation with a rocket ship of opportunity"
Alexander Wissner-Gross
Scientific Advisory Board
A Small, Mighty Force—Seasoned Builders. Visionary Futurists. Relentless Scientists.
We are a hand-picked team of world-class pharmacists, proven dealmakers, pioneering technologists, and leading immunologists—advancing a platform designed to shift inflammatory care upstream.
In a $10T+ inflammation-driven world, precision beats scale—and vision defines the winners. We’re here to redefine what’s possible.